Research and analysis

Joint position paper from ACNFP and COT on establishing provisional ADI for pure form CBD in foods

Joint position paper from the Advisory Committee on Novel Foods and Processes (ACNFP) and Committee on Toxicity (COT) on intake for cannabidiol (CBD) in foods.

• From: Advisory Committee on Novel Foods and Processes and Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment
• Published: 12 October 2023

Documents

Lay summary

HTML

Joint position paper from the Advisory Committee on Novel Foods and Processes (ACNFP) & Committee on Toxicity (COT) on establishing a provisional acceptable daily intake (ADI) for pure form (≥98%) cannabidiol (CBD) in foods, based on new evidence.

HTML

Joint position paper from the Advisory Committee on Novel Foods and Processes (ACNFP) & Committee on Toxicity (COT) on establishing a provisional acceptable daily intake (ADI) for pure form (≥98%) cannabidiol (CBD) in foods, based on new evidence.

PDF, 255 KB, 17 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email acnfp@food.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

DOI: https://doi.org/10.46756/sci.fsa.zcg392

This page publishes a joint position paper from the Advisory Committee on Novel Foods and Processes (ACNFP) and the Committee on Toxicity (COT) on establishing a provisional acceptable daily intake (ADI) for cannabidiol (CBD) of 98% or greater purity in foods. The paper was developed following a call by the Food Standards Agency (FSA) for data to support applications for CBD as a novel food ingredient. New toxicological and human data submitted by applicants were reviewed by a joint ACNFP and COT subgroup established to assess the evidence. The ADI is described as provisional because it may be refined as further scientific evidence becomes available. The subgroup also identified gaps in data, particularly relating to reproductive and developmental toxicity and immunotoxicity. As a result, additional caution is advised for vulnerable groups, including pregnant or breastfeeding women, individuals trying to conceive, children, immunocompromised individuals and people taking certain medications. This is reflected in the FSA advice on the consumption of CBD.

Published 12 October 2023